Harness Therapeutics Ltd. has raised fresh financing to further develop its technology for upregulating the translation of mRNA into proteins, and in particular to take on a previously undruggable target in Huntington’s disease.
Omniamed Co. Ltd. and Pohang University of Science & Technology have patented compounds acting as nitric oxide (NO) scavengers and reported to be useful for the treatment of cancer, allergy, obesity, myelofibrosis, autoimmune diseases, inflammatory, cardiovascular and neurological disorders, among others.
Nanjing Synnocare Pharmaceutical Technology Co. Ltd. and Tianjin Synnocare Biomedical Technology Co. Ltd. have jointly developed new N-myristoyltransferase 1 (NMT1) inhibitors reported to be useful for the treatment of cancer, malaria, leishmaniasis, rhinovirus and HIV infections.
Work at Aston University has led to the identification of tissue transglutaminase (TGM2) inhibitors potentially useful for the treatment of fibrosis, thrombosis, cancer, AIDS, inflammation, transplant rejection, neurodegenerative and autoimmune diseases, among others.
Exelixis Inc. has synthesized fused pyrazole derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
A University of California patent describes new inhibitors of GTPase KRAS, particularly KRAS G12D mutant, reported to be useful for the treatment of cancer.
Hypoxia-inducible factors (HIFs) are crucial to maintain oxygen homeostasis by regulating cellular metabolic adaptation under hypoxia conditions. Depletion of factor inhibiting HIF (FIH), an enzyme that negatively regulates the activity of the HIF-1α isoform, has been associated with reductions in hepatic steatosis and body mass in mice.
Researchers from Fundación Jiménez Díaz and affiliated organizations have published data from a study that aimed to identify new genes involved in the progression of atherosclerosis, a chronic multifactorial inflammatory disease characterized by the accumulation of lipids and leukocytes within the arterial wall.
Seed Therapeutics Inc.’s ST-01156 has been awarded orphan drug designation for the treatment of Ewing sarcoma as well as rare pediatric disease designation by the FDA.
RSS
